Registry Study on "Control Nocturnal Hypertension to Reach the Target "
Ambulatory blood pressure monitoring (ABPM) is a major innovation in the history of hypertension diagnosis. In clinical practice, the most well established indication for using ABPM is to identify patients who have high BP readings in the office but normal readings during usual daily activities outside of this setting
| Condition(s) | Nocturnal Hypertension |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | Ambulatory blood pressure monitoring (ABPM) is a major innovation in the history of hypertension diagnosis. In clinical practice, the most well established indication for using ABPM is to identify patients who have high BP readings in the office but normal readings during usual daily activities outside of this setting or vice versa, and to identify varying 24-h BP profiles. However, in recent years, there has been increasing interest in BP values during sleep, and nocturnal BP is now recognized to be superior to daytime BP in predicting fatal and nonfatal cardiovascular events (stroke, myocardial infarction, and cardiovascular death), especially in medicated patients. The current direction in the management of hypertension is toward earlier and lower BP control for 24 hours, including the |
| Who can participate | Inclusion Criteria: * Age 50-79 years old * Clinical diagnosed hypertension with the use of antihypertensive drugs * Nocturnal hypertension ( nocturnal systolic blood pressure ≥ 130 mmHg and/or nocturnal diastolic blood pressure ≥ 80 mmHg) * A 24-hour ambulatory blood pressure monitoring was performed with validated equipment. * Willing to provide information about disease history and blood biochemical test data within 6 months. * Sign the informed consent Exclusion Criteria: * Without antihypertensive drug use * Hospitalized hypertension patients * Non-compliant patient |
| Ages | 50 Years to 79 Years |
| Sex | All |
| Lead sponsor | Shanghai Institute of Hypertension |
| Locations | Shanghai, Shanghai Municipality, China |
| Start date | 2019-12-01 |
| NCT ID | NCT04137549 |
| Official listing | https://clinicaltrials.gov/study/NCT04137549 |